Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 18/20 | 0.69 |
| ▸ | CHRM2 | P08172 | 10/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.40 |
| ▸ | KMO | O15229 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23522997 | 1.00 | CHRM4 (0.69) | CHRM4CHRM2CYP1A2CYP3A4CYP2B6 | |
| SCHEMBL23522995 | 1.00 | CHRM4 (0.69) | CHRM4CHRM2CYP1A2CYP3A4CYP2B6 | |
| SCHEMBL23523417 | 0.92 | CHRM4 (0.66) | CHRM4CHRM2CYP1A2CYP3A4CYP2B6 | |
| SCHEMBL23523414 | 0.92 | CHRM4 (0.66) | CHRM4CHRM2CYP1A2CYP3A4CYP2B6 | |
| SCHEMBL23523419 | 0.92 | CHRM4 (0.66) | CHRM4CHRM2CYP1A2CYP3A4CYP2B6 | |
| SCHEMBL23523035 | 0.91 | CHRM4 (0.65) | CHRM4CHRM2CYP1A2CYP3A4CYP2B6 | |
| SCHEMBL23523032 | 0.91 | CHRM4 (0.65) | CHRM4CHRM2CYP1A2CYP3A4CYP2B6 | |
| SCHEMBL23523038 | 0.91 | CHRM4 (0.65) | CHRM4CHRM2CYP1A2CYP3A4CYP2B6 | |
| SCHEMBL23523278 | 0.86 | CHRM4 (0.70) | CHRM4CHRM2CYP1A2CYP3A4CYP2B6 | |
| SCHEMBL23523280 | 0.86 | CHRM4 (0.70) | CHRM4CHRM2CYP1A2CYP3A4CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116902-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2024-04-11 | — | — | US | claimed |
| US-20220213069-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2022-07-07 | — | — | US | claimed |
| US-20210188820-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2021-06-24 | — | — | US | claimed |
| US-12577234-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2026-03-17 | — | — | US | disclosed |
| US-20240116902-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2024-04-11 | — | — | US | disclosed |
| US-11820757-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820757-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2023-11-21 | — | — | US | disclosed |
| US-20220213069-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2022-07-07 | — | — | US | disclosed |
| US-20220213069-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2022-07-07 | — | — | US | disclosed |
| US-11299481-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2022-04-12 | — | — | US | disclosed |
| US-11299481-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2022-04-12 | — | — | US | disclosed |
| US-20210188820-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2021-06-24 | — | — | US | disclosed |
| US-20210188820-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2021-06-24 | — | — | US | disclosed |
| WO-2019079783-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY (US) | 2019-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820757-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | CHRM2, CHRM3, CHRM4 | CHRM4 3/4885CHRM2 1/4885CYP1A2 2151/4885 |
| US-20240116902-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM2, CHRM3, CHRM4 | CHRM4 3/4885CHRM2 1/4885CYP1A2 2151/4885 |
| US-11299481-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | CHRM2, CHRM3, CHRM4 | CHRM4 3/4885CHRM2 1/4885CYP1A2 2151/4885 |
| US-20220213069-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM2, CHRM3, CHRM4 | CHRM4 3/4885CHRM2 1/4885CYP1A2 2151/4885 |
| US-20210188820-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM2, CHRM3, CHRM4 | CHRM4 3/4885CHRM2 1/4885CYP1A2 2151/4885 |
| US-12577234-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | CHRM3, CHRM4, CHRM2 | CHRM4 2/4885CHRM2 3/4885CYP1A2 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.